Supplementary Material: Protection against Omicron BA.2 reinfection conferred by primary Omicron or pre-Omicron infection with and without mRNA vaccination

Supplementary Table 1. Protection against any Omicron BA.2 reinfection and against symptomatic Omicron BA.2 reinfection associated with pre-Omicron and Omicron BA.1 primary infection (PI) with/without vaccination
Supplementary Table 2. Protection against Omicron BA.2 reinfection induced by primary pre-Omicron or Omicron BA.1 infection with/without vaccination, by reinfection definition: ≥30-day interval versus ≥90-day interval between positive NAAT test results
Supplementary Figure 1. Study population4

Supplementary Table 1. Protection against any Omicron BA.2 reinfection and against symptomatic Omicron BA.2 reinfection associated with pre-Omicron and Omicron BA.1 primary infection (PI) with/without vaccination.

	Any Omicron	BA.2 infection	Symptomatic Omicron BA.2 infection		
	Unadjusted	Adjusted	Unadjusted	Adjusted	
Infection history and	protection	protection ^b	protection	protection ^b	
vaccination status ^a	(95% CI)	(95% CI)	(95% CI)	(95% CI)	
Pre-Omicron PI					
Unvaccinated	36% (19, 50)	38% (19, 53)	49% (21, 68)	51% (22, 69)	
1-dose vaccinated	27% (15, 38)	56% (47, 63)	73% (64, 79)	74% (66, 80)	
2-dose vaccinated	48% (41, 54)	69% (64, 73)	80% (75, 84)	81% (76, 85)	
3-dose vaccinated	51% (45, 56)	70% (66, 74)	81% (77, 85)	83% (78, 86)	
Omicron BA.1 PI					
Unvaccinated	73% (67, 78)	72% (65, 78)	87% (80, 91)	86% (79, 91)	
1-dose vaccinated	87% (75, 94)	89% (78, 95)	97% (89, 99)	97% (89, 99)	
2-dose vaccinated	92% (91, 94)	96% (95, 96)	98% (97, 98)	98% (97, 98)	
3-dose vaccinated	93% (92, 94)	96% (95, 97)	98% (98, 99)	98% (98, 99)	
No prior infection				_	
Unvaccinated	Referent	Referent	Referent	Referent	
1-dose vaccinated	-9% (-39, 14)	9% (-19, 31)	45% (16, 64)	43% (11, 63)	
2-dose vaccinated	-17% (-29, -5)	35% (27, 42)	58% (49, 66)	61% (52, 69)	
3-dose vaccinated	4% (-6, 13)	46% (40, 52)	67% (59, 73)	70% (62, 75)	

^b Total number of doses administered before study inclusion regardless timing with respect to prior primary infection (before and/or after primary infection)

Abbreviations: CI, confidence interval; PI, primary infection

^a Logistic regression models adjusted for age, sex, type of employment, facility, indication for testing and epidemiological week. Exposures are compared to unvaccinated individuals without infection history.

Supplementary Table 2. Protection against Omicron BA.2 reinfection induced by primary pre-Omicron or Omicron BA.1 infection with/without vaccination, by reinfection definition: ≥30-day interval versus ≥90-day interval between positive NAAT test results


	Omicron BA.2 infection			Omicron BA.2 infection				
	≥30-day definition of reinfection				≥90-day definition of reinfection			
Infection history			Unadjusted	Adjusted			Unadjusted	Adjusted
and vaccination	Cases	Controls	effectiveness	effectiveness ^b	Cases	Controls	effectiveness	effectiveness ^b
status ^a			(95% CI)	(95% CI)			(95% CI)	(95% CI)
Pre-Omicron PI	2521	7360			2521	7360		
Unvaccinated	109	265	36% (19, 50)	38% (19, 53)	109	265	36% (18, 50)	38% (18, 53)
1-dose vaccinated	342	729	27% (15, 38)	56% (47, 63)	342	727	27% (14, 38)	57% (48, 64)
2-dose vaccinated	897	2665	48% (41, 54)	69% (64, 73)	897	2665	48% (41, 54)	69% (64, 74)
3-dose vaccinated	1173	3701	51% (45, 56)	70% (66, 74)	1173	3703	51% (44, 56)	71% (67, 75)
Omicron BA.1 PI	659	12315			470	9118		
Unvaccinated	125	727	73% (67, 78)	72% (65, 78)	91	604	77% (70, 82)	73% (65, 79)
1-dose vaccinated	9	109	87% (75, 94)	89% (78, 95)	7	84	87% (72, 94)	87% (71, 94)
2-dose vaccinated	262	5322	92% (91, 94)	96% (95, 96)	207	4290	93% (91, 94)	96% (95, 96)
3-dose vaccinated	263	6157	93% (92, 94)	96% (95, 97)	165	4140	94% (93, 95)	96% (95, 97)
No prior infection and unvaccinated	672	1043	Reference	Reference	672	1049	Reference	Reference

^a Total number of doses administered before study inclusion regardless timing with respect to prior primary infection.

Abbreviations: CI, confidence interval; NAAT, nucleic acid amplification test

^b Logistic regression models adjusted for age, sex, type of employment, facility, indication for testing and epidemiological week. Exposures are compared to unvaccinated individuals without infection history.

Supplementary Figure 1. Study population



Abbreviations: NAAT, nucleic acid amplification test